NIGHTINGALE HEALTH OYJ |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.7 EUR | +1.19% |
|
+17.24% | +52.33% |
| Apr. 16 | Finland’s Nightingale Health Plots US Expansion | MT |
| Apr. 16 | Nightingale Health to Establish A Laboratory in the United States | CI |
| Sales 2024 * | 4.7M 5.03M | Sales 2025 * | 8.7M 9.32M | Capitalization | 103M 110M |
|---|---|---|---|---|---|
| Net income 2024 * | -16M -17.13M | Net income 2025 * | -16M -17.13M | EV / Sales 2024 * | 7.8 x |
| Net cash position 2024 * | 65.9M 70.56M | Net cash position 2025 * | 52.2M 55.89M | EV / Sales 2025 * | 5.79 x |
| P/E ratio 2024 * |
-6.3
x | P/E ratio 2025 * |
-6.3
x | Employees | 81 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 53.93% |
More Fundamentals
* Assessed data
More news
Latest transcript on Nightingale Health Oyj
More press releases
| 1 day | +1.19% | ||
| 1 week | +17.24% | ||
| Current month | +63.46% | ||
| 1 month | +65.37% | ||
| 3 months | +50.18% | ||
| 6 months | +62.84% | ||
| Current year | +52.33% |
1 week
1.54
1.73
1 month
1.011.73
Current year
0.981.73
1 year
0.801.73
3 years
0.806.59
5 years
0.806.75
10 years
0.806.75
| Managers | Title | Age | Since |
|---|---|---|---|
Peter Würtz
FOU | Founder | - | 01-12-31 |
Satu Saksman
FOU | Founder | 48 | 01-12-31 |
Pasi Soininen
FOU | Founder | - | 01-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 59 | 20-12-16 | |
| Chairman | 61 | 20-12-31 | |
Olli Pekka Karhi
BRD | Director/Board Member | 61 | 14-12-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-24 | 1.7 | +1.19% | 109,897 |
| 24-04-23 | 1.68 | -1.18% | 107,643 |
| 24-04-22 | 1.7 | +8.28% | 259,558 |
| 24-04-19 | 1.57 | +0.32% | 207,525 |
| 24-04-18 | 1.565 | +7.93% | 314,941 |
Delayed Quote Nasdaq Helsinki, April 24, 2024 at 11:24 am EDT
More quotes
Nightingale Health Oyj is a Finland-based health technology company that aims to promote preventative health and help people stay healthy. The blood analysis technology developed by Nightingale measures a broad group of biomarkers from a single blood sample, recognizing individual disease risks. The Company provides people with comprehensive insights on health, helps them make better decisions regarding their health and connects them with healthcare experts that offer preventative services for maintaining health. Nightingale Health Oy is the Parent Company in the Nightingale Group. The Group comprises the parent Companyâs subsidiaries: Nightingale Health United States Inc, Nightingale Health Asia Pte Ltd, Nightingale Health Japan KK as well as NG Health Sweden AB. The Company owns and independently oversees two laboratories in Finland, in Helsinki and Kuopio, and one laboratory in Tokyo, Japan.
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
1.7
EUR
Average target price
1.25
EUR
Spread / Average Target
-26.47%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +52.33% | 108M | |
| +4.16% | 32.45B | |
| +12.62% | 7.26B | |
| +20.83% | 3.84B | |
| -11.41% | 3.43B | |
| -27.11% | 1.31B | |
| -34.31% | 1.11B | |
| +4.25% | 919M | |
| -23.45% | 856M | |
| -38.17% | 840M |
- Stock Market
- Equities
- HEALTH Stock
